why choose us

First received: August 22, 2023

Clinical Trial: Intratumoral PH-762 for Cutaneous Carcinoma

Study Status: Completed

Recruit Status: RECRUITING

Condition: Squamous Cell Carcinoma of the Skin

Study Type: INTERVENTIONAL


Official Title: Dose Escalation Study of Neoadjuvant Intratumoral PH-762 for Cutaneous Squamous Cell Carcinoma, Melanoma, or Merkel Cell Carcinoma

Brief Summary: The goal of this clinical trial is to evaluate the safety and tolerability of intratumoral injections of PH-762 in squamous cell carcinoma, melanoma, or Merkel cell carcinomas of the skin, to understand what the body does to the PH-762, and to observe how the tumor responds to the drug.Participants will receive four injections of PH-762 at weekly intervals, into a single tumor, followed by surgical removal of the tumor approximately two weeks later.

Read more